Ascendis Pharma

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

Ascendis scores FDA approval for weekly dwarfism drug

Children with achondroplasia will soon have the option of a once-weekly - rather than daily - injection, courtesy of Ascendis' newly approved Yuviwel.

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

News

FDA okays Ascendis hypoparathyroidism drug at second attempt

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma.

Readout for AZ's hypoparathyroidism drug raises questions

Ascendis scores FDA approval for weekly dwarfism drug

Novo puts $285m into monthly GLP-1 based on Ascendis tech

FDA okays Ascendis hypoparathyroidism drug at second attempt

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Ascendis Pharma

Editor's Picks